Olympus is committed to advancing the detection, diagnosis, and treatment of upper GI conditions, including Barrett’s esophagus and GERD. By partnering with healthcare professionals, we deliver innovative solutions designed to support confident clinical decision-making and improve patient outcomes.
Our EVIS X1™ Endoscopy System offers a suite of advanced imaging technologies to support Barrett’s assessment and surveillance.NBI™ technology remains a standard approach for evaluating mucosal and vascular patterns1 and has been shown across multiple studies to reduce procedure time by decreasing the number of biopsies required compared to the Seattle protocol.2
Complementing this foundation, TXI™ technology enhances mucosal texture, brightness, and color contrast,1 and RDI™ technology enhances the visibility of deep blood vessels compared to white light.1
Beyond visualization, Olympus provides a comprehensive ecosystem of support, including clinical education, onboarding, and field-based expertise, to help teams integrate these technologies into practice. With a dedicated network of specialists, we partner with you to optimize performance, workflow, and patient care.
At Olympus, we believe innovation goes beyond technology. It’s about empowering clinicians with the tools, training, and support needed to deliver high-quality care.
NBI, TXI, and RDI are trademarks of Olympus Corporation, Olympus America, Inc., and/or their affiliates.
NBI™, TXI™, RDI™ technologies are not intended to replace histopathological sampling as a means of diagnosis.
1. Data on file with Olympus (DC00489968).2. Data on file with Olympus as of 07/02/2010